Dipòsit Digital de Documents de la UAB
Publicación
Artículo científico (JournalArticle)
A RAD51 assay feasible in routine tumor samples calls inhibitor response beyond BRCA mutation
Poly(-ribose) polymerase () inhibitors (i) are effective in cancers with defective homologous recombination repair (), including 1/2-related cancers. A test to identify additional -deficient tumors will help to extend their use in new indications. We evaluated the activity of the i olaparib in patient-derived tumor xenografts (s) from breast cancer () patients and investigated mechanisms of sensitivity through exome sequencing, 1 promoter methylation analysis, and immunostaining of proteins, including 51 nuclear foci. In an independent panel, the predictive capacity of the 51 score and the homologous recombination deficiency () score were compared. To examine the clinical feasibility of the 51 assay, we scored archival breast tumor samples, including 2-related hereditary cancers. The 51 score was highly discriminative of i sensitivity versus PARPi resistance in s and outperformed the genomic test. In clinical samples, all 2-related tumors were classified as -deficient by the 51 score. The functional biomarker 51 enables the identification of i-sensitive and broadens the population who may benefit from this therapy beyond 1/2-related cancers.
Proyecto:
Instituto de Salud Carlos III FISPI17/01080
,
Ministerio de Economía y Competitividad CP14/00228
,
Ministerio de Economía y Competitividad CP16/00034
,
Ministerio de Economía y Competitividad PI12-02606
,
Ministerio de Economía y Competitividad PI12/02585
,
Ministerio de Economía y Competitividad PI15-00355
,
Ministerio de Economía y Competitividad PI13/01711
,
Ministerio de Economía y Competitividad PI16/01218
,
Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-540